Hassan Raza: The JAK2 V617F Revolution
Hassan Raza, Consultant Hematologist and Transfusion Medicine Specialist, shared a post on LinkedIn about a recent article by Ayalew Tefferi, published in Haematologica, adding:
”The JAK2 V617F Revolution: A Landmark in Hematology
‘If you want to discover new ideas, revisit old discoveries.’
The identification of JAK2 V617F in 2005 transformed our understanding of myeloproliferative neoplasms (MPNs), reshaping their diagnosis, classification, and therapeutic approaches.
A fascinating reflection on how a single molecular discovery changed hematology.
Worth revisiting: A landmark paper revisited by Ayalew Tefferi in Haematologica, November 2026.”
Title: The JAK2 V617F revolution in myeloproliferative neoplasms
Author: Ayalew Tefferi
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian
-
Nov 11, 2026, 14:45ITP Is More Than a Platelet Count: Why Patient Perspectives Matter – ITP Australia and New Zealand